Literature DB >> 25910299

A comparison of the effects of infliximab, adalimumab, and pentoxifylline on rats with non-alcoholic steatohepatitis.

Mustafa Yalcin1, Mesut Akarsu, Aslı Celik, Ozgul Sagol, Sunay Tunali, Ozge Ertener, Göksel Bengi, Hale Akpinar.   

Abstract

BACKGROUND/AIMS: Non-alcoholic steatohepatitis (NASH) lacks effective medical treatment. Since tumor necrosis factor alpha (TNF-α) plays an important role in NASH pathogenesis, we aimed to investigate drugs affecting TNF-α as possible treatment options during the development of NASH.
MATERIALS AND METHODS: A total of 35 rats were divided into five groups and evaluated over a 6 week period. One group received a normal diet alone or in combination with the administration of infliximab, adalimumab or pentoxifylline.
RESULTS: NASH was successfully established in the MCD diet group. Levels of TNF-α were effectively suppressed in the three groups that received anti-TNF agents. No statistically significant differences were observed between the three agents in terms of the histological NASH score.
CONCLUSION: Our study showed that the anti-TNF agents infliximab, adalimumab, and pentoxifylline effectively suppress TNF-α. Although these drugs did not prevent the development of NASH, they were able to slightly reverse the NASH histopathology score and positively affect liver function tests.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25910299     DOI: 10.5152/tjg.2014.5121

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  5 in total

Review 1.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

Review 2.  Role of cAMP and phosphodiesterase signaling in liver health and disease.

Authors:  Banrida Wahlang; Craig McClain; Shirish Barve; Leila Gobejishvili
Journal:  Cell Signal       Date:  2018-06-11       Impact factor: 4.315

Review 3.  Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article.

Authors:  Che-Yung Chao; Robert Battat; Alex Al Khoury; Sophie Restellini; Giada Sebastiani; Talat Bessissow
Journal:  World J Gastroenterol       Date:  2016-09-14       Impact factor: 5.742

Review 4.  NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome.

Authors:  Valerio Rosato; Mario Masarone; Marcello Dallio; Alessandro Federico; Andrea Aglitti; Marcello Persico
Journal:  Int J Environ Res Public Health       Date:  2019-09-14       Impact factor: 3.390

5.  TNF-alpha inhibitor adalimumab attenuates endotoxin induced cardiac damage in rats.

Authors:  Selim Durmaz; Tünay Kurtoğlu; Emin Barbarus; Nükhet Eliyatkın; Mustafa Yılmaz
Journal:  Acta Cir Bras       Date:  2020-04-03       Impact factor: 1.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.